Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03475706 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
A Phase 2 study, sponsored by Velicept Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 438
- Enrollment target
NCT03475706 is a Phase 2 study that has completed, run by Velicept Therapeutics. The registered enrollment target is 438 participants.
The verdict
NCT03475706, a Phase 2 study, has completed, sponsored by Velicept Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 438 participants
- Enrollment target
Study Summary
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate release low dose or high dose tablets, compared to matched placebo, administered twice daily for 12 weeks to adult female subjects with overactive bladder symptoms (frequency, urgency, and predominantly urgency incontinence) for at least 6 months.
Interventions
- DRUG Matching Placebo
- DRUG Solabegron immediate release tablets, low dose
- DRUG Solabegron immediate release tablets, high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 438 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03475706
The ClinicalTrials.gov registry entry for NCT03475706 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 438 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Velicept Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Matching Placebo is the first listed.
NCT03475706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03475706 about?
NCT03475706 is a clinical study titled "Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women". This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate release low dose or high dose tablets, compared to matched placebo, administered twice daily for 12 weeks to adult f...
What is the current status of trial NCT03475706?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 438 participants. The study started on 2018-02-19. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT03475706?
The interventions under investigation include: Matching Placebo (DRUG), Solabegron immediate release tablets, low dose (DRUG), Solabegron immediate release tablets, high dose (DRUG).
Who is sponsoring clinical trial NCT03475706?
This trial is sponsored by Velicept Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.